Found: 6
Select item for more details and to access through your institution.
Comprehensive analyses of A 12-metabolism-associated gene signature and its connection with tumor metastases in clear cell renal cell carcinoma.
- Published in:
- BMC Cancer, 2023, v. 23, n. 1, p. 1, doi. 10.1186/s12885-023-10740-6
- By:
- Publication type:
- Article
Publisher Correction: N6-methyladenosine-modified ALDH9A1 modulates lipid accumulation and tumor progression in clear cell renal cell carcinoma through the NPM1/IQGAP2/AKT signaling pathway.
- Published in:
- 2024
- By:
- Publication type:
- Correction Notice
N6-methyladenosine-modified ALDH9A1 modulates lipid accumulation and tumor progression in clear cell renal cell carcinoma through the NPM1/IQGAP2/AKT signaling pathway.
- Published in:
- Cell Death & Disease, 2024, v. 15, n. 7, p. 1, doi. 10.1038/s41419-024-06896-z
- By:
- Publication type:
- Article
ENO2 as a Biomarker Regulating Energy Metabolism to Promote Tumor Progression in Clear Cell Renal Cell Carcinoma.
- Published in:
- Biomedicines, 2023, v. 11, n. 9, p. 2499, doi. 10.3390/biomedicines11092499
- By:
- Publication type:
- Article
NAT10‐mediated ac<sup>4</sup>C‐modified ANKZF1 promotes tumor progression and lymphangiogenesis in clear‐cell renal cell carcinoma by attenuating YWHAE‐driven cytoplasmic retention of YAP1.
- Published in:
- Cancer Communications, 2024, v. 44, n. 3, p. 361, doi. 10.1002/cac2.12523
- By:
- Publication type:
- Article
N6‐methyladenosine‐modified DBT alleviates lipid accumulation and inhibits tumor progression in clear cell renal cell carcinoma through the ANXA2/YAP axis‐regulated Hippo pathway.
- Published in:
- Cancer Communications, 2023, v. 43, n. 4, p. 480, doi. 10.1002/cac2.12413
- By:
- Publication type:
- Article